# Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma

> **NCT01473628** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 81 (actual)

## Conditions studied

- Ann Arbor Stage I Grade 1 Follicular Lymphoma
- Ann Arbor Stage I Grade 2 Follicular Lymphoma
- Ann Arbor Stage II Grade 1 Follicular Lymphoma
- Ann Arbor Stage II Grade 2 Follicular Lymphoma

## Interventions

- **OTHER:** Clinical Observation
- **RADIATION:** Radiation Therapy
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT01473628
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-05-20
- **Primary completion:** 2027-05-20
- **Final completion:** 2027-05-20
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01473628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01473628, "Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01473628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*